SpringWorks Therapeutics Inc (NASDAQ: SWTX) kicked off on Tuesday, up 4.65% from the previous trading day, before settling in for the closing price of $39.39. Over the past 52 weeks, SWTX has traded in a range of $20.19-$53.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 39.79%. With a float of $65.79 million, this company’s outstanding shares have now reached $73.49 million.
In an organization with 305 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 93.59%, operating margin of -217.92%, and the pretax margin is -203.09%.
SpringWorks Therapeutics Inc (SWTX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of SpringWorks Therapeutics Inc is 11.56%, while institutional ownership is 102.00%. The most recent insider transaction that took place on Sep 03 ’24, was worth 1,988,033. In this transaction Chief Executive Officer of this company sold 49,000 shares at a rate of $40.57, taking the stock ownership to the 1,063,368 shares. Before that another transaction happened on Sep 03 ’24, when Company’s Chief Operating Officer sold 20,000 for $40.65, making the entire transaction worth $812,954. This insider now owns 229,600 shares in total.
SpringWorks Therapeutics Inc (SWTX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.45 earnings per share (EPS), lower than consensus estimate (set at -1.1) by -0.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.79% per share during the next fiscal year.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Trading Performance Indicators
Take a look at SpringWorks Therapeutics Inc’s (SWTX) current performance indicators. Last quarter, stock had a quick ratio of 6.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -2.01 in one year’s time.
Technical Analysis of SpringWorks Therapeutics Inc (SWTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.33 million. That was better than the volume of 1.0 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 89.87%. Additionally, its Average True Range was 2.08.
During the past 100 days, SpringWorks Therapeutics Inc’s (SWTX) raw stochastic average was set at 84.32%, which indicates a significant decrease from 96.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.79% in the past 14 days, which was higher than the 47.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.80, while its 200-day Moving Average is $39.87. However, in the short run, SpringWorks Therapeutics Inc’s stock first resistance to watch stands at $42.18. Second resistance stands at $43.14. The third major resistance level sits at $44.59. If the price goes on to break the first support level at $39.77, it is likely to go to the next support level at $38.32. The third support level lies at $37.36 if the price breaches the second support level.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) Key Stats
The company with the Market Capitalisation of 3.07 billion has total of 74,386K Shares Outstanding. Its annual sales at the moment are 5,450 K in contrast with the sum of -325,100 K annual income. Company’s last quarter sales were recorded 49,300 K and last quarter income was -53,530 K.
